坤泰胶囊治疗绝经综合征的系统评价
Meta分析显示坤泰胶囊与HRT在Kupperman指数、有效率、E2及FSH水平上无统计学差异(P>0.05),但不良事件总发生率显著低于HRT[OR=0.28, 95% CI (0.17, 0.45)]。纳入研究方法学质量低,结论需更多严格设计的大规模随机临床试验验证。
要点
- 坤泰胶囊与HRT在改善绝经综合征症状及激素水平上无统计学差异。
- 坤泰胶囊不良事件总发生率显著低于HRT[OR=0.28, 95% CI (0.17, 0.45)]。
- 纳入研究方法学质量低,疗效结论需谨慎解读。
核心结论
- 坤泰胶囊治疗绝经综合征可能有效且副作用风险较低。
- 因纳入研究方法学质量低,需更多严格设计的大规模随机临床试验评估疗效。
研究设计与样本
- 纳入17项随机对照试验,共1455例参与者,比较坤泰胶囊与安慰剂或激素替代疗法(HRT)。
- 采用Cochrane偏倚风险方法评估质量,用Review Manager 5.2软件进行Meta分析。
主要发现
- Kupperman指数(KI)[WMD=0.51, 95% CI (-0.04, 1.06)]、KI有效率[OR=1.21, 95% CI (0.72, 2.04)]、E2水平[WMD=-15.18, 95% CI (-33.93, 3.56)]及FSH水平[WMD=-3.46, 95% CI (-7.2, 0.28)]在坤泰胶囊与HRT组间均无统计学差异(P>0.05)。
- 与HRT相比,坤泰胶囊可显著降低不良事件总发生率[OR=0.28, 95% CI (0.17, 0.45)]。
关键数值与推荐
- 纳入的17项RCT方法学质量低。
- 坤泰胶囊与HRT在KI、KI有效率、E2及FSH水平上无统计学差异(P>0.05)。
- 坤泰胶囊不良事件总发生率显著低于HRT[OR=0.28, 95% CI (0.17, 0.45)]。
临床怎么用
- 坤泰胶囊可作为绝经综合征的治疗选择之一,尤其适用于关注不良反应风险的患者。
- 临床决策时应考虑现有证据方法学质量较低,疗效结论尚需高质量试验确认。
局限性
- 纳入的17项RCT方法学质量低。
- 需要更多严格设计的大规模随机临床试验评估坤泰胶囊的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Kuntai capsule has been widely used for the treatment of menopausal syndrome in China for long time. We conducted this review to assess efficacy and safety of Kuntai capsule for the treatment of menopausal syndrome. METHODS: We searched studies in PubMed, ClinicalTrials, the Cochrane Library, China National Knowledge Infrastructure Database(CNKI), China Science and Technology Journal Database (VIP), Wan fang Database and Chinese Biomedical Literature Database(CBM) until November 20, 2014. Randomized trials on Kuntai capsule for menopausal syndrome, compared with placebo or hormone replacement therapy (HRT) were included. Two reviewers independently retrieved the randomized controlled trials (RCTs) and extracted the information. The Cochrane risk of bias method was used to assess the quality of the included studies, and a Meta-analysis was conducted with Review Manager 5.2 software. RESULTS: A total of 17 RCTs (1455 participants) were included. The studies were of low methodological quality. Meta-analysis indicated that there was no statistical difference in the Kupperman index (KI) [WMD=0.51, 95% CI (-0.04, 1.06)], the effective rate of KI [OR=1.21, 95% CI (0.72, 2.04)], E2 level [WMD=-15.18, 95% CI (-33.93, 3.56)], and FSH level [WMD=-3.46, 95% CI (-7.2, 0.28)] after treatment between Kuntai versus HRT group (P>0.05). However, Compared with HRT, Kuntai capsule could significantly reduce the total incidence of adverse events [OR=0.28, 95% CI (0.17, 0.45)]. CONCLUSIONS: Kuntai capsule may be effective for treating menopausal syndrome and lower risk of side effects. The studies we analyzed were of low methodological quality. Therefore, more strictly designed large-scale randomized clinical trials are needed to evaluate the efficacy of Kuntai capsule in menopausal syndrome.
引用
- Zhou Q, Tao J, Song H, et al. Chinese herbal medicine Kuntai capsule for treatment of menopausal syndrome: a systematic review of randomized clinical trials. Complement Ther Med. 2016. PMID: 27912959. doi:10.1016/j.ctim.2016.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。